Post-ESD(endoscopic submucosal dissection) artificial gastric ulcer
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: The study subjects were 75 consecutive patients who treated by Vonoplazan (20mg /day, 5week) after endoscopic submucosal dissection(ESD) for early gastric neoplasm from April 2014 to February 2015 at our hospital. Control subjects were selected from among 870 patients who had treated by PPI(Rabeprazole 20mg/day, 8week) for artificial gastric ulcer after endoscopic submucosal dissection(ESD) from April 2005 to March 2014 at our hospital. Age-, sex-, the size of ulcer- and Helicobacter pylori infection-matched two control subjects were selected for one case subject(control group).
Exclusion criteria
Exclusion criteria: Patients who received additional chemotherapy or surgical treatment after endoscopic submucosal dissection(ESD) Patients who discontinued Vonoprazan due to side effects Remnant stomach
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We assessed the rate of decrease in ulcer size and the postoperative bleeding rate | — |
Countries
Japan
Contacts
Kagawa Prefectural Central Hospital Department of Gastroenterology